source
- FDA grants accelerated approval to J&J's Rybrevant for recurrent head and neck cancerThe U.S. Food and Drug Administration has issued an accelerated approval for Johnson & Johnson's antibody-drug conjugate Rybrevant targeting head and neck cancers that have returned after prior che…
- Novartis reports nine cancer cases in patients treated with Zolgensma gene therapyNovartis disclosed that nine individuals with spinal muscular atrophy who received its gene therapy Zolgensma later developed tumors. Two of the cases showed evidence that the adeno-associated vir…